An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'
I'm LongbridgeAI, I can summarize articles.AstraZeneca and Bristol Myers Squibb are in early-stage talks to merge, potentially creating a cancer-drug giant. However, analysts describe the move as 'odd' and perplexing. Concerns include significant regulatory hurdles due to overlapping oncology portfolios, which could trigger antitrust scrutiny. Additionally, critics question the strategic logic, noting AstraZeneca's strong pipeline and Bristol Myers' upcoming key data readouts make such a combination unexpected despite potential valuation benefits.
By Steve Goldstein & Jaimy Lee
The reported tie-up talks are moving stocks. Analysts are puzzled.
"Odd" is the word that analysts are using to describe a potential Bristol-Myers Squibb tie-up with AstraZeneca.
AstraZeneca and Bristol Myers Squibb are reportedly in talks to merge and create one of the world's largest drugmakers - and a cancer-drug powerhouse.
AstraZeneca shares (AZN) (UK:AZN) closed 6.9% lower on Monday, while Bristol Myers Squibb's stock (BMY) was flat. The Financial Times first reported the talks on Sunday, characterized as early stage.
AstraZeneca declined to comment. Bristol Myers has yet to respond.
Both companies are already leaders in oncology, and a tie-up could create "an oncology powerhouse," particularly in four categories that are all popular in drug development today: immuno-oncology, targeted therapies, antibody drug conjugates, and hematology oncology, according to RBC Capital Markets analyst Trung Huynh.
At the same time, given the scale of both companies' cancer businesses, analysts believe any deal would face tough regulatory hurdles, both in the U.S., where Bristol Myers is based, and the U.K., which is home to AstraZeneca. Cancer drugs made up 44% of AstraZeneca's revenue in 2025, while Bristol Myers' cancer business generated about half of its sales.
The "combined oncology scale likely raises real antitrust concerns," Huynh wrote in a note. "Expect lengthy review and possible divestitures."
Bank of America analysts led by Sachin Jain used the word "odd" to describe the potential combination - for both companies.
Jain said the worry for AstraZeneca investors is that it may be taken as a signal of a lack of confidence in its pipeline, a comment of particular note after a rare late-stage failure last month for its heart drug Wainua in patients with transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM.
But the analysts said it's also that Bristol Myers would be in deal talks, given it has so much potential market-moving news due over the next year, including readouts for admilparant, an idiopathic pulmonary fibrosis medication; blood-clot drug milvexian; and Cobenfy, which is approved for schizophrenia and is being evaluated for psychosis associated with Alzheimer's disease dementia.
Bristol Myers' stock has soared 22% so far this year, while AstraZeneca's stock is down 7%.
Jefferies analysts led by Michael Leuchten had a similar take.
"We are a bit perplexed by the news," they wrote. "Of course, financial accretion can look good and maybe more cash generation would allow for more R&D. But if there is one company that doesn't need financial engineering, it's [AstraZeneca] in our view."
The obvious attraction, however, would be valuation - Bristol's earnings multiple, on 2027 estimated earnings, is 10, versus 14 for AstraZeneca, according to FactSet. But it's cheap for a reason, with patent expirations coming up.
-Steve Goldstein -Jaimy Lee
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-03-26 1659ET